Luspatercept for Lower-Risk MDS: Data From the COMMANDS Trial
Rami Komrokji, MD, summarizes data presented at ASCO 2023 from the COMMANDS trial on the role of luspatercept in lower-risk MDS.
Source: onclive.com
Page 7 - Data From News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Data From. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Data From Today - Breaking & Trending Today
Prognosis of Those with Systemic Sclerosis Sine Scleroderma
New data drawn from the EUSTAR database made clear several key insights into this subset of systemic sclerosis patients, with survival and skin manifestations being highlighted.
Source: hcplive.com
Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
COPENHAGEN, Denmark--(BUSINESS WIRE)--Jun 27, 2023--
Source: joplinglobe.com
Genmab and AbbVie Announce Positive Topline Results from
Company Announcement Based on the topline results from the EPCORE™ NHL-1 clinical trial, Genmab and AbbVie will engage with global regulatory authorities...
Source: globenewswire.com
AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
/PRNewswire/ -- AbbVie (NYSE: ABBV) and Genmab (Nasdaq: GMAB) today announced topline results from the follicular lymphoma (FL) cohort of the Phase 1/2 EPCORE™...
Source: prnewswire.com